S&P Futures
4,075.75 -8.50 (-0.21%) Dow Futures
33,998.00 -48.00 (-0.14%) Nasdaq Futures
12,190.25 -32.00 (-0.26%) Russell 2000 Futures
1,915.20 -4.30 (-0.22%) Crude Oil
79.93 +0.25 (+0.31%) Gold
1,942.10 -3.50 (-0.18%)
Design Therapeutics, Inc. (DSGN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.49 |
| Open | 8.47 |
| Bid | 7.85 x 900 |
| Ask | 9.31 x 800 |
| Day's Range | 8.25 - 8.63 |
| 52 Week Range | 6.94 - 26.30 |
| Volume | |
| Avg. Volume | 560,637 |
| Market Cap | 462.377M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DSGN
Related Research
- Design Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 12/21/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast monthArgus Research
- GlobeNewswire
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for the Treatment of Fuchs Endothelial Corneal Dystrophy Administered as an Eye Drop; IND Expected in 2023 Advancing Myotonic Dystrophy Type-1 GeneTACTM Lead Molecules; IND Expected in 2024 Conference Call to be Held Today at 4:30pm ET CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nas
- GlobeNewswire
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022 Dosing Initiated in the Multiple-Ascending Dose Phase 1 Trial of DT-216; Trial Completion Anticipated in Mid-2023 Strong Financial Position with $344.2 Million in Cash and Securities to Support Multi-Year Operating Runway and Further Advancement of GeneTAC™ Platform CARLSBAD, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-s
- GlobeNewswire
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022CARLSBAD, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-216, as a potential treatment for Friedreich ataxia (FA) will be presented during an oral sessio
